Menieres Disease Treatment Trends and Research Review

Research volume on Ménière’s disease has surged over the last three decades, but a new scoping review reveals a troubling decline in the quality of how this research is reported. The study, published in *The Laryngoscope*, found that while the number of high-level studies has multiplied, adherence to standard diagnostic and outcome guidelines has significantly worsened. This “quality paradox” threatens the validity of promising new treatment trends.

## A Tri-Decade Review Uncovers a “Quality Paradox”

A team from the University of Toronto, led by Ofir Zavdy, Teeraya Piyajarawong, Seamus Boyle, and John Rutka, set out to map the evidence for Ménière’s disease from 1994 to 2024. Ménière’s is an inner ear disorder characterized by episodes of vertigo, hearing loss, and tinnitus. Despite established diagnostic guidelines from the American Academy of Otolaryngology–Head and Neck Surgery (AAO-HNS), treatment approaches vary widely.

The researchers conducted a scoping review, a method designed to map the key concepts and types of evidence in a field. They systematically searched major databases like PubMed and Cochrane for randomized controlled trials and prospective cohort studies published in English. Each study was graded using the Oxford Centre for Evidence-Based Medicine (CEBM) system, and its adherence to AAO-HNS guidelines and CONSORT reporting standards was analyzed. Their goal was to identify trends in both research volume and methodological rigor.

## Research Volume is Up, But Reporting Standards are Down

The analysis of 257 included studies revealed a clear and concerning split. The sheer volume of research on Ménière’s disease has grown substantially. The number of Level 2 studies, considered good quality individual studies, quadrupled. Level 3 studies tripled.

However, this increase in quantity has been accompanied by a significant drop in quality. The review found that adherence to AAO-HNS diagnostic criteria fell to 73%. More strikingly, compliance with the AAO-HNS recommended criteria for measuring treatment outcomes plummeted to just 34%. This means a majority of recent studies are not measuring success or failure in a standardized way, making it difficult to compare results or build a reliable evidence base. The authors label this disconnect the “Quality Paradox.”

## The Clinical Shift Toward Preservation and Precision

Beyond reporting issues, the review documented a clear evolution in how clinicians manage Ménière’s disease. The trend is moving decisively away from destructive procedures and toward interventions that preserve hearing and function.

There is now a greater emphasis on visualizing the presumed cause of Ménière’s—endolymphatic hydrops—using advanced MRI. For treatment, intratympanic steroid injections are being favored over intratympanic gentamicin, which carries a higher risk of hearing damage. The use of cochlear implantation for patients with severe hearing loss from Ménière’s has increased. Conversely, the use of positive-pressure devices, which once had interest, has declined. This shift reflects a more patient-centered, precision medicine approach that prioritizes long-term quality of life and hearing health. This philosophy aligns with modern management strategies for related conditions like tinnitus, where approaches such as Tinnitus Retraining Therapy also focus on habituation and improving daily function.

## Why Standardized Reporting is Non-Negotiable

The core conclusion from Zavdy and colleagues is urgent. The promising clinical shift toward better treatments is built on a foundation of evidence that is becoming less reliable. If studies do not diagnose patients consistently or measure outcomes using the same metrics, their findings cannot be trusted or effectively compared.

The authors state plainly that journals must enforce standardized reporting as a nonnegotiable prerequisite for publication. Without this, the field risks advancing based on flawed or incomparable data, which could ultimately slow progress and harm patient care. Ensuring research integrity is a fundamental step for all hearing-related science, whether studying Ménière’s disease, misophonia and hyperacusis, or the efficacy of new digital tools.

## Implications for Patients and Future Research

For patients, this review highlights both hope and caution. The move toward hearing-preserving treatments is a positive development that could lead to better long-term outcomes. However, the “quality paradox” means that headlines about new treatments must be read carefully. Patients and clinicians should look for studies that explicitly follow AAO-HNS guidelines to ensure the results are credible.

For the research community, the path forward is clear. Future studies must commit to rigorous methodology and transparent reporting. As technology introduces new possibilities, like the use of AI in therapeutic sound design, maintaining these high standards will be essential. Only with a solid, reliable evidence base can the field continue to improve care for the complex symptoms of Ménière’s disease and related auditory disorders.

The full scoping review, “Ménière’s Disease: A Tri-Decade Scoping Review of Treatment Trends and Evidence Quality,” is available via its PMID: 42053150 and DOI: 10.1002/lary.70596.